Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-28T00:40:40.607Z Has data issue: false hasContentIssue false
  • English
  • Français

Immunization with High-Dose Intradermal Recombinant Hepatitis B Vaccinein Healthcare Workers Who Failed to Respond to Intramuscular Vaccination

Published online by Cambridge University Press:  02 January 2015

Robert E. Levitz ,
Brian W. Cooper  and
Helen C. Regan
Robert E. Levitz
Affiliation:
Division of Infectious Diseases, Hartford Hospital, Hartford, andthe University of Connecticut Medical School, Farmington, Hartford, Connecticut
Brian W. Cooper*
Affiliation:
Division of Infectious Diseases, Hartford Hospital, Hartford, andthe University of Connecticut Medical School, Farmington, Hartford, Connecticut
Helen C. Regan
Affiliation:
Division of Employee Health, Hartford Hospital, Hartford, Connecticut
*
Division of Infectious Diseases, Hartford Hospital, 80 Seymour St., Hartford, CT 06102
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To achieve immunity to hepatitis B in healthcare workers who failed to respond to intramuscular vaccination and boosters.

Design:

An open prospective study of intradermal vaccination with recombinant hepatitis B vaccine.

Setting:

A large community hospital in Connecticut.

Participants:

Healthcare workers including physicians, nurses, and laboratory workers.

Results:

Immunization with high-dose intradermal recombinant hepatitis B vaccine, given in up to four doses, achieved immunity in 88% of healthcare workers who had previously been nonimmune.

Conclusions:

We conclude that intradermal vaccination is efficacious in the majority of healthcare workers who failed to respond to intramuscular vaccine. Further studies, including randomized comparisons with intramuscular vaccine as well as studies of cell-mediated immunity, appear warranted.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 16 , Issue 2 , February 1995 , pp. 88 - 91
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1995 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Department of Labor, Occupational Safety and Health Administration. Occupational exposure to bloodborne pathogens: rules and regulations. Federal Register 1991;56;64004–64182.Google Scholar
2. Wood, RC, MacDonald, KL, White, KE, Hedberg, CW, Hanson, M, Osterholm, MT Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health-care workers. JAMA 1993;270:2935–2939.CrossRefGoogle ScholarPubMed
3. Roome, AJ, Walsh, SJ, Cartter, ML, Hadler, JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993;270:2931–2934.CrossRefGoogle ScholarPubMed
4. Szmuness, W, Stevens, CE, Harley, EJ, et al. Hepatitis B vaccine; demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N Engl J Med 1980;303:833–841.CrossRefGoogle Scholar
5. Shaw, FE Jr, Guess, HA, Roets, JM, et al. Effect of anatomic injection site, age, and smoking on the immune response to hepatitis B vaccination. Vaccine 1989;7:425–430.CrossRefGoogle ScholarPubMed
6. Weber, DJ, Rutala, WA, Samsa, GP, Santimaw, JE. Lemon, SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985;254:3187–3189.CrossRefGoogle ScholarPubMed
7. Weissman, JY, Tsuchiyose, MM, Tong, MJ, et al. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA 1988;260:1734–1738.CrossRefGoogle Scholar
8. Nagafuchi, S, Kashiwag, S, Okada, K, et al. Reversal of nonrespon-ders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel. JAMA 1991;265:2679–2683.CrossRefGoogle ScholarPubMed
9. Horowitz, MM, Ershler, WB, McKinney, WP: Battiola, RJ. Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. Ann Intern Med 1988;108:185–189.CrossRefGoogle ScholarPubMed
10. Parish, DC, Muecke, HW, Joiner, TA, Pope, WT, Hadler, SC. Immunogenicity of low-dose intradermal recombinant DNA hepatitis B vaccine. South Med J 1991;84:426–430.CrossRefGoogle ScholarPubMed
11. McMaster, KR III, Roper, JK, Carter, JB. Intradermal Hepatitis B vaccination in a 300-bed primary care hospital: experience with a recombinant vaccine in a four-dose schedule. Am infect Control 1993;21:283–288.CrossRefGoogle Scholar
12. Wainwright, RB, McMahon, BJ, Bulkow, LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population, JAMA 1989;261:2362–2366.CrossRefGoogle Scholar
13. Hadler, SC, Francis, DP, Maynard, JE, et al. long-term immuno-genicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986;315:209–214.CrossRefGoogle Scholar
14. Jin, Y, Shih, J, Berkower, I. Human T cell response to the surface antigen of hepatitis B virus (HBsAg). J Exp Med 1988;168:293–306.CrossRefGoogle Scholar
15. Centers for Disease Control. Inadequate immune response among public safety workers receiving intradermal vaccination against hepatitis B-United States, 1990-1991. MMWR 1991; 40:569–572.Google Scholar
16. Cockshott, W, Thompson, G, Howlett, L, Seeley, E. Intramuscular or intralipomatous injections? N Engl J Med 1982;307:356–358.CrossRefGoogle ScholarPubMed
17. Platt, J, Grant, B, Eddy, A, Michael, A. Immune cell populations in cutaneous delayed-type hypersensitivity. } Exp Med 1983;158:1227–1242.Google ScholarPubMed